Clinical trials of Pfizer COVID-19 jab flawed. Negative side effects were covered up. Contains nanoparticles  | WHAT REALLY HAPPENED X-Frame-Options: SAMEORIGIN

Clinical trials of Pfizer COVID-19 jab flawed. Negative side effects were covered up. Contains nanoparticles 

According to a published report, the much hyped up jabs from the United States developed by Pfizer and Moderna, are special fat nanoparticles containing a fragment of the COVID-19 RNA.

The British scientific journal The BMJ published on Wednesday (Nov 3) a report stating that the US-based multinational pharmaceutical corporation Pfizer, during clinical trials of their COVID-19 vaccine, violated scientific norms, including falsifying data, unblinded patients and covered up negative side effects.

The publication noted that “A regional director who was employed at the research organization Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.”

The regional director of the Ventavia Research Group, Brook Jackson, who helped in the Pfizer trials, contacted The BMJ to start an investigation, after she reported massive clinical trial violations to Pfizer and was fired in September 2020.

Jackson gave The BMJ much evidence, consisting of dozens of internal company documents, photos, video and audio recordings, which convinced editors at the journal about her statements being true. During the investigation and the verifying of information, the British journal received further evidence which confirmed that the vaccine trials did not meet the standards declared by Pfizer.

The investigation highlighted inconsistencies to include Pfizer executive board being apprehensive about the audits launched by the US Food and Drug Administration (FDA) and other regulatory agencies. As a result, this led to the falsification of data, in addition where some of the information was being covered up.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA